Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shubulade Smith

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Evidence-Based Mental Health|April 29, 2008
Metabolic syndrome common in people with psychotic disorders, particularly in users of high potency antipsychoticsShubulade Smith
International Review of Psychiatry (Abingdon, England)|November 5, 2010
Gender differences in antipsychotic prescribingShubulade Smith
Journal of Clinical Psychopharmacology|July 2, 2003
Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practiceShubulade Smith
BMJ (Clinical Research Ed.)|May 25, 2002
Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessedOliver Howes, Shubulade Smith
The American Journal of Psychiatry|April 2, 2004
Alendronic acid for antipsychotic-related osteopeniaOliver Howes, Shubulade Smith
BMJ (Clinical Research Ed.)|April 9, 2022
The NHS is not an island-tackling racial disparities in healthcareShubulade Smith, Raj Mohan
Journal of the Royal Society of Medicine|November 4, 2011
Schizophrenia as segmental progeriaEvangelos Papanastasiou, Fiona Gaughran, Shubulade Smith
Bjpsych Bulletin|July 29, 2020
Clozapine and COVID-19Edward Silva, Siobhan Gee, Shubulade Smith, et al.
The Lancet. Psychiatry|August 22, 2021
Advance directives reduce friction over involuntary treatmentKevin Ariyo, Claire Henderson, Steve Gilbert, et al.
Current Medical Research and Opinion|October 7, 2004
Comment on Hyperprolactinaemia and antipsychotic therapy in schizophreniaOliver D Howes, Shubulade Smith, Kathy J Aitchison
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Evidence-Based Mental Health|April 29, 2008
Metabolic syndrome common in people with psychotic disorders, particularly in users of high potency antipsychoticsShubulade Smith
International Review of Psychiatry (Abingdon, England)|November 5, 2010
Gender differences in antipsychotic prescribingShubulade Smith
Journal of Clinical Psychopharmacology|July 2, 2003
Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practiceShubulade Smith
BMJ (Clinical Research Ed.)|May 25, 2002
Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessedOliver Howes, Shubulade Smith
The American Journal of Psychiatry|April 2, 2004
Alendronic acid for antipsychotic-related osteopeniaOliver Howes, Shubulade Smith
BMJ (Clinical Research Ed.)|April 9, 2022
The NHS is not an island-tackling racial disparities in healthcareShubulade Smith, Raj Mohan
Journal of the Royal Society of Medicine|November 4, 2011
Schizophrenia as segmental progeriaEvangelos Papanastasiou, Fiona Gaughran, Shubulade Smith
Bjpsych Bulletin|July 29, 2020
Clozapine and COVID-19Edward Silva, Siobhan Gee, Shubulade Smith, et al.
The Lancet. Psychiatry|August 22, 2021
Advance directives reduce friction over involuntary treatmentKevin Ariyo, Claire Henderson, Steve Gilbert, et al.
Current Medical Research and Opinion|October 7, 2004
Comment on Hyperprolactinaemia and antipsychotic therapy in schizophreniaOliver D Howes, Shubulade Smith, Kathy J Aitchison
Pageof 6